Table 2.

Rates and rate ratios of heart failure admissions across levels of kidney function among participants with chronic kidney disease

		Rate Ratio (95% CI)
	Number at risk (Total number of events)	Crude rate, per 100 pys (95% bootstrapped CIs)	Model 1	Model 2	Model 3
Overall	3791 (1706)	5.8 (5.2, 6.4)
eGFR stage
eGFR ≥ 45	1714 (437)	3.1 (2.5, 3.7)	1.0 (Ref.)	1.0 (Ref.)	1.0 (Ref.)
eGFR 30-44	1379 (766)	7.4 (6.2, 8.6)	2.1 (1.7, 2.7)	1.9 (1.5, 2.4)	1.7 (1.3, 2.2)
eGFR < 30	698 (503)	10.3 (8.4, 12.2)	2.9 (2.2, 3.8)	2.5 (1.9, 3.3)	2.2 (1.7, 2.9)
Albuminuria
uACR < 30	1629 (383)	2.9 (2.3, 3.5)	1.0 (Ref.)	1.0 (Ref.)	1.0 (Ref.)
uACR 30 - < 300	1001 (510)	6.6 (5.3, 8.0)	2.3 (1.8, 3.1)	1.9 (1.4, 2.6)	1.9 (1.5, 2.6)
uACR ≥ 300	1161 (813)	9.7 (8.3, 11.2)	3.8 (3.0, 4.9)	2.6 (2.0, 3.5)	2.6 (1.9, 3.5)
CKD category
eGFR ≥ 45, uACR < 300	1401 (253)	2.2 (1.7, 2.7)	1.0 (Ref.)	1.0 (Ref.)	1.0 (Ref.)
eGFR < 45, uACR < 300	1229 (640)	6.9 (5.7, 8.1)	2.7 (2.0, 3.6)	2.5 (1.9, 3.4)	2.3 (1.7, 3.0)
eGFR ≥ 45, uACR > 300	313 (184)	7.7 (5.4, 10.1)	4.1 (2.8, 6.1)	2.9 (1.9, 4.4)	2.9 (1.9, 4.4)
eGFR < 45, uACR > 300	848 (629)	10.6 (8.8, 12.3)	4.6 (3.5, 6.2)	3.2 (2.3, 4.4)	3.0 (2.2, 4.1)

All rate ratios with p-value<0.05

eGFR= estimated glomerular filtration rate; uACR= urine albumin-to-creatinine-ratio

Model 1: age, sex, and race/ethnicity

Model 2: model 1 + diabetes, history of cardiovascular disease, use of lipid-lowering medications, smoking, systolic blood pressure, and body mass index

Model 3: model 2 + use of diuretics, angiotensin-converting-enzyme inhibitors/aldosterone receptor blockers, β-blockers